Novo Nordisk leads the GLP-1 weight-loss market and is now prioritizing direct-to-consumer obesity care. Berenberg maintained its buy rating, citing NovoCare's redesign and new telehealth partnerships as key drivers for stronger demand in oral GLP-1s like the daily Wegovy pill.
What This Means for Wegovy Users
The company aims to make treatment as simple as online shopping, bypassing specialist referrals. Berenberg notes that demand for oral GLP-1s may favor consumers wanting quick access, privacy, and an easy start.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
- Revamped NovoCare online pharmacy enhances user experience.
- Telehealth tie-ups lift interest in the daily pill.
- Channel checks from aesthetic physicians signal potential upside to Wegovy forecasts.
This consumer-friendly push positions Wegovy for broader adoption in evidence-based weight management.